Alisha Akinsete, Onjona B Hossain, Ilir Agalliu, Dawn M Wahezi, Ellen J Silvers, Irene Blanco, Tamar Rubinstein, Cristina Gonzalez
{"title":"Racial Implicit Bias, Treatment Recommendations, and Perceived Compliance in the Care of Juvenile Idiopathic Arthritis.","authors":"Alisha Akinsete, Onjona B Hossain, Ilir Agalliu, Dawn M Wahezi, Ellen J Silvers, Irene Blanco, Tamar Rubinstein, Cristina Gonzalez","doi":"10.1002/acr2.70082","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Racial implicit bias may contribute to health disparities in juvenile idiopathic arthritis (JIA) outcomes by impacting provider medical decision-making. Our study assessed racial and racial-medical compliance implicit biases of an international pediatric rheumatology community and investigated whether their biases impact treatment recommendations for patients with JIA.</p><p><strong>Methods: </strong>A web-based survey, which included a randomized vignette describing either a White or Black patient with JIA, was sent to pediatric rheumatology providers. Participants were prompted to select the best patient management option and to complete two implicit association tests (IATs): race and race compliance. Student's t-tests or analysis of variance were used to compare IAT D-scores between or across groups; all tests were two-sided with P < 0.05 considered statistically significant. Logistic regression models were used to examine associations for two outcomes of interest: recommendation of either adequate (methotrexate monotherapy) or aggressive (methotrexate and adalimumab combination) treatment with each IAT D-score by each vignette.</p><p><strong>Results: </strong>Overall, 165 pediatric rheumatologists completed the survey. Providers showed a slight pro-White bias in the race IAT (mean D-score ± SD 0.26 ± 0.5) and race-medical compliance IAT (mean D-score ± SD 0.16 ± 0.43). Although not statistically significant, a one-point increase in IAT D-scores was associated with a lower likelihood that providers would choose aggressive treatment versus adequate treatment in the Black vignette (odds ratio [OR] 0.55, 95% confidence interval [CI] 0.20-1.47; P = 0.23), and a greater likelihood that providers would choose aggressive treatment in the White vignette (OR 4.07, 95% CI 0.74-22.24; P = 0.11).</p><p><strong>Conclusion: </strong>Implicit bias was not associated with treatment recommendations. Further studies are needed to better evaluate the impact of implicit bias.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 8","pages":"e70082"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR open rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.70082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Racial implicit bias may contribute to health disparities in juvenile idiopathic arthritis (JIA) outcomes by impacting provider medical decision-making. Our study assessed racial and racial-medical compliance implicit biases of an international pediatric rheumatology community and investigated whether their biases impact treatment recommendations for patients with JIA.
Methods: A web-based survey, which included a randomized vignette describing either a White or Black patient with JIA, was sent to pediatric rheumatology providers. Participants were prompted to select the best patient management option and to complete two implicit association tests (IATs): race and race compliance. Student's t-tests or analysis of variance were used to compare IAT D-scores between or across groups; all tests were two-sided with P < 0.05 considered statistically significant. Logistic regression models were used to examine associations for two outcomes of interest: recommendation of either adequate (methotrexate monotherapy) or aggressive (methotrexate and adalimumab combination) treatment with each IAT D-score by each vignette.
Results: Overall, 165 pediatric rheumatologists completed the survey. Providers showed a slight pro-White bias in the race IAT (mean D-score ± SD 0.26 ± 0.5) and race-medical compliance IAT (mean D-score ± SD 0.16 ± 0.43). Although not statistically significant, a one-point increase in IAT D-scores was associated with a lower likelihood that providers would choose aggressive treatment versus adequate treatment in the Black vignette (odds ratio [OR] 0.55, 95% confidence interval [CI] 0.20-1.47; P = 0.23), and a greater likelihood that providers would choose aggressive treatment in the White vignette (OR 4.07, 95% CI 0.74-22.24; P = 0.11).
Conclusion: Implicit bias was not associated with treatment recommendations. Further studies are needed to better evaluate the impact of implicit bias.